Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Endocrine 2CNS 2Breast 2Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Thyroid Neoplasms 8Carcinoma, Medullary 6Thyroid Cancer, Papillary 5Lung Neoplasms 4Breast Neoplasms 4Thyroid Diseases 3Sarcoma 3Neoplasms 3Colonic Neoplasms 3Central Nervous System Neoplasms 3Wilms Tumor 2Thoracic Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasms by Site 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lung Diseases 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Head and Neck Neoplasms 2Glioma 2Ependymoma 2

Interventions

Gemcitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3selpercatinib 2parathyroid hormone-related peptide (1-36) 2niraparib 2Ocoxin 2Musculoskeletal Manipulations 2Metformin 2Clomiphene 2Cisplatin 2repotrectinib 1relacorilant 1pralsetinib 1pembrolizumab 1napabucasin 1lutetium Lu 177 dotatate 1fluorodopa F 18 1copper dotatate CU-64 1anlotinib 1adrenosterone 1Ultrasonography 1Thalidomide 1Sunitinib 1Spironolactone 1Parathyroid Hormone-Related Protein 1Parathyroid Hormone 1Paclitaxel 1Octreotide 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endocrine System Diseases × selpercatinib × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡